Arthrosi raises $153M in Series E to complete two Phase 3 gout trials

There’s a contest brewing between two San Diego biotechs looking to create the next gout medicine. Arthrosi Therapeutics uncorked a $153 million Series E on Wednesday to complete two Phase 3 ...